» Articles » PMID: 21092288

Hypofractionated Radiotherapy After Conservative Surgery for Breast Cancer: Analysis of Acute and Late Toxicity

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2010 Nov 25
PMID 21092288
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A variety of hypofractionated radiotherapy schedules has been proposed after breast conserving surgery in the attempt to shorten the overall treatment time. The aim of the present study is to assess acute and late toxicity of using daily fractionation of 2.25 Gy to a total dose of 45 Gy to the whole breast in a mono-institutional series.

Methods: Eighty-five women with early breast cancer were assigned to receive 45 Gy followed by a boost to the tumour bed. Early and late toxicity were scored according to the Radiation Therapy Oncology Group criteria. For comparison, a group of 70 patients with similar characteristics and treated with conventional fractionation of 2 Gy to a total dose of 50 Gy in 25 fractions followed by a boost, was retrospectively selected.

Results: Overall median treatment duration was 29 days for hypofractionated radiotherapy and 37 days for conventional radiotherapy. Early reactions were observed in 72/85 (85%) patients treated with hypofractionation and in 67/70 (96%) patients treated with conventional fractionation (p = 0.01). Late toxicity was observed in 8 patients (10%) in the hypofractionation group and in 10 patients (15%) in the conventional fractionation group, respectively (p = 0.4).

Conclusions: The hypofractionated schedule delivering 45 Gy in 20 fractions shortened the overall treatment time by 1 week with a reduction of skin acute toxicity and no increase of late effects compared to the conventional fractionation. Our results support the implementation of hypofractionated schedules in clinical practice.

Citing Articles

Breast Cancer Adjuvant Radiotherapy and Chemotherapy Sequencing: Sequential, Concomitant, or What Else? A Comprehensive Review of the Adjuvant Combinations Journey.

Lazzari G, Montagna A, DAndrea B, Bianculli A, Calice G, Tucciariello R J Clin Med. 2024; 13(20).

PMID: 39458200 PMC: 11508402. DOI: 10.3390/jcm13206251.


Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients.

Lu Y, Hui B, Yang D, Li Y, Li B, Zhou L BMC Cancer. 2024; 24(1):181.

PMID: 38321381 PMC: 10845660. DOI: 10.1186/s12885-024-11918-2.


Mexican radiationdermatitis management consensus.

Tenorio C, De la Mata D, Felix Leyva J, Poitevin-Chacon A, Queijeiro M, Gutierrez G Rep Pract Oncol Radiother. 2022; 27(5):914-926.

PMID: 36523808 PMC: 9746638. DOI: 10.5603/RPOR.a2022.0101.


Risk factors and specific cancer types of second primary malignancies in patients with breast cancer receiving adjuvant radiotherapy: a case-control cohort study based on the SEER database.

Xia C, Qin L, Wang Y, Yao L, Shia B, Wu S Am J Cancer Res. 2022; 12(6):2744-2756.

PMID: 35812050 PMC: 9251704.


Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort.

Aldraimli M, Osman S, Grishchuck D, Ingram S, Lyon R, Mistry A Adv Radiat Oncol. 2022; 7(3):100890.

PMID: 35647396 PMC: 9133391. DOI: 10.1016/j.adro.2021.100890.


References
1.
Olivotto I, Weir L, Kim-Sing C, Bajdik C, Trevisan C, Doll C . Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996; 41(1):7-13. DOI: 10.1016/s0167-8140(96)91824-1. View

2.
Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

3.
Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7(6):467-71. DOI: 10.1016/S1470-2045(06)70699-4. View

4.
Plataniotis G, Dale R . Biologically effective dose-response relationship for breast cancer treated by conservative surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(2):512-7. DOI: 10.1016/j.ijrobp.2009.05.013. View

5.
Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bentzen S, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618):1098-107. PMC: 2277488. DOI: 10.1016/S0140-6736(08)60348-7. View